Next-Generation Sequencing Workflow Simplification

This document is a leadership perspective that outlines Illumina's strategy to simplify next-generation sequencing (NGS) workflows. It details the evolution of NGS since its inception in 2005, highlighting the significant cost reductions from approximately $1 million to around $200 for whole-genome sequencing. The text explains how Illumina aims to enhance the user experience by streamlining sample preparation and data analysis processes. Innovations such as the MiSeq i100 Series and the constellation technology are presented as solutions to reduce the complexity and time required for sequencing workflows. Additionally, the document discusses advancements in software, particularly the DRAGEN software, which automates data analysis and improves structural variant detection. The importance of rapid and accurate genomic analysis in oncology and rare disease research is emphasized, along with the introduction of TruSight Oncology Comprehensive, which aids in identifying tumor biomarkers. Overall, the document illustrates Illumina's commitment to advancing genomic discovery and improving human health.